FindTrial
Sign In

STUDY ON THE ROLE OF ASPIRIN IN PREVENTING PRETERM BIRTH

LOW DOSE ASPIRIN FOR THE PREVENTION OF SPONTANEOUS PRETERM LABOUR IN WOMEN AT RISK FOR PRETERM BIRTH

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031734
Enrollment
100
Registered
2021-03-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: Z00-Z99- Factors influencing health status and contact with health services

Interventions

Intervention1: Aspirin: Low dose aspirin will be given to antenatal women between 6 to 16 weeks of gestation at risk for preterm birth apart from routine antenatal treatment 75 mg once daily dose wil

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Antenatal Women between 6 to 16 weeks of gestation Singleton Pregnancy History of previous spontaneous preterm birth and/or PPROM or history of second trimester abortion

Exclusion criteria

Exclusion criteria: Previous indicated preterm birth for maternal or fetal reasons Contraindications to aspirin use Major fetal malformations in current or previous pregnancy Multifetal gestation Moderate /severe anaemia Medical comorbidities Uterine anomalies and cervical insufficiency At risk for preeclampsia

Design outcomes

Primary

MeasureTime frame
To compare incidence of preterm birth at less than 37 weeks of gestation between aspirin and non aspirin groupsTimepoint: 9 months—

Secondary

MeasureTime frame
To compare maternal complications and neonatal outcomes between aspirin and non aspirin groupsTimepoint: 9 months—

Countries

India

Contacts

Public ContactTanu Sharma

PGIMER

surivanita@yahoo.co.in9914209346

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026